Analysts predict that Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) will announce earnings per share of ($0.10) for the current quarter, Zacks reports. Two analysts have made estimates for Brainstorm Cell Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.18). Brainstorm Cell Therapeutics reported earnings per share of $0.02 during the same quarter last year, which would suggest a negative year-over-year growth rate of 600%. The business is expected to report its next earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.61) to ($0.47). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.69) to ($0.10). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Monday, October 29th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.05).
A number of research analysts have weighed in on BCLI shares. Maxim Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Brainstorm Cell Therapeutics in a research report on Monday, December 17th. HC Wainwright set a $11.00 price objective on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Monday, October 29th. Finally, Dawson James reiterated a “buy” rating on shares of Brainstorm Cell Therapeutics in a research note on Tuesday, December 18th.
Shares of BCLI traded down $0.08 during mid-day trading on Monday, hitting $3.37. The company had a trading volume of 558,223 shares, compared to its average volume of 114,440. Brainstorm Cell Therapeutics has a 1-year low of $2.88 and a 1-year high of $5.35. The stock has a market capitalization of $69.99 million, a PE ratio of -12.96 and a beta of 1.41.
A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Renaissance Technologies LLC increased its stake in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 29.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 115,400 shares of the biotechnology company’s stock after buying an additional 26,299 shares during the period. Renaissance Technologies LLC owned about 0.56% of Brainstorm Cell Therapeutics worth $450,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.44% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Further Reading: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.